⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL367290 | 0.75 | — | — | |
| SCHEMBL6319825 | 0.74 | — | — | |
| SCHEMBL379255 | 0.74 | — | — | |
| SCHEMBL3853943 | 0.74 | — | — | |
| SCHEMBL3380190 | 0.72 | — | — | |
| SCHEMBL3037201 | 0.72 | — | — | |
| SCHEMBL6718304 | 0.71 | — | — | |
| SCHEMBL11452344 | 0.70 | — | — | |
| SCHEMBL20814339 | 0.70 | — | — | |
| SCHEMBL2425940 | 0.69 | — | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 24 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-0077826-A4 | AGENTS FOR ARRESTING FULMINATING INFECTION. | EVREKA INC (US) | 1984-01-16 | — | — | EP | claimed |
| EP-0077826-A1 | AGENTS FOR ARRESTING FULMINATING INFECTION. | EVREKA INC (US) | 1983-05-04 | — | — | EP | claimed |
| WO-1982003770-A1 | METHOD AND AGENTS FOR ARRESTING FULMINATING INFECTION | EVREKA INC (US) | 1982-11-11 | — | — | WO | claimed |
| US-4286067-A | Article of manufacture comprising semipermeable polymer and dextran derivative | ALZA CORPORATION (US) | 1981-08-25 | — | — | US | claimed |
| CN-107082782-A | Substituted xanthine and its application method | 海德拉生物科学有限公司 | 2017-08-22 | — | — | CN | disclosed |
| CN-105143229-B | Substituted xanthines and methods of use thereof | 海德拉生物科学有限公司 | 2017-06-30 | — | — | CN | disclosed |
| CN-105143229-A | Substituted xanthines and methods of use thereof | HYDRA BIOSCIENCES INC | 2015-12-09 | — | — | CN | disclosed |
| US-20100330113-A1 | Vaccine Antigens | INTERVET INTERNATIONAL B.V. | 2010-12-30 | — | — | US | disclosed |
| US-7811583-B2 | Antigens and vaccines against Piscirickettsia salmonis | INTERVET INTERNATIONAL B.V. (NL) | 2010-10-12 | — | — | US | disclosed |
| US-7754223-B2 | Piscirickettsia salmonis antigens and use thereof | EUROGENTEC SA (BE) | 2010-07-13 | — | — | US | disclosed |
| US-20090162391-A1 | VACCINE ANTIGENS FROM PISCIRICKETTSIA SALMONIS | SCHERING-PLOUGH ANIMAL HEALTH CORPORATION | 2009-06-25 | — | — | US | disclosed |
| US-7417120-B2 | Purified Stat proteins and methods of purifying thereof | THE ROCKEFELLER UNIVERSITY (US) | 2008-08-26 | — | — | US | disclosed |
| US-20050196758-A1 | Novel enoyl reductases and methods of use thereof | ROCK CHARLES O (US) | 2005-09-08 | — | — | US | disclosed |
| US-6911336-B2 | GNK interacting amino acid decarboxylase and methods of use thereof | IMMUNEX CORPORATION (US) | 2005-06-28 | — | — | US | disclosed |
| US-6780984-B2 | DIAGNOSING CANCER IN HUMANS; OBTAIN TISSUE SAMPLE, DETERMINE CONCENTRATION OF CALRETICULIN IN SAMPLE, COMPARE TO CONTROL, EVALUATE FOR CANCER | NORTHWESTERN UNIVERSITY | 2004-08-24 | — | — | US | disclosed |
| US-20020197690-A1 | GNK interacting amino acid decarboxylase and methods of use thereof | IMMUNEX CORPORATION | 2002-12-26 | — | — | US | disclosed |
| EP-0362283-A4 | BOVINE INTERLEUKIN-1_G(A) | — | 1991-10-16 | — | — | EP | disclosed |
| EP-0362283-A1 | BOVINE INTERLEUKIN-1 ALPHA. | IMMUNEX CORP (US) | 1990-04-11 | — | — | EP | disclosed |
| WO-1988009382-A1 | BOVINE INTERLEUKIN-1alpha | IMMUNEX CORPORATION (US) | 1988-12-01 | — | — | WO | disclosed |
| EP-0289129-A2 | High purity protein A preparation | REPLIGEN CORPORATION (US) | 1988-11-02 | — | — | EP | disclosed |